What is West Pharmaceutical Services's market cap?

West Pharmaceutical Services (WST) has a market capitalization of $25.0B and trades on NYSE.

What is West Pharmaceutical Services's revenue and profitability?

West Pharmaceutical Services generated $3.2B in trailing twelve-month revenue with net income of $542.7M, representing a net margin of 16.8%. Gross margin stands at 36.3%, with free cash flow of $458.0M. These figures are based on the Q1 2026 filing.

Who are West Pharmaceutical Services's competitors?

West Pharmaceutical Services's key competitors include AptarGroup, Inc., Stevanato Group, Becton, Dickinson and Company, and others. These companies compete in similar markets and product categories.

Who does West Pharmaceutical Services partner with?

West Pharmaceutical Services's notable partners include Daikyo Seiko, Ltd..

What subsidiaries does West Pharmaceutical Services have?

West Pharmaceutical Services's subsidiaries include Medimop Medical Projects Ltd., The Tech Group.

Where is West Pharmaceutical Services headquartered?

West Pharmaceutical Services is headquartered in United States of America and employs approximately 10,600 people. It has been publicly traded since 1973.

West Pharmaceutical Services

WST

West Pharmaceutical Services is a global leader in the design and manufacture of high-quality containment and delivery systems for injectable medicines.

Market cap

$24.99B+56.5%

Revenue$3.2B+11.2%

Net income$542.7M+16.2%

Free cash flow$458.0M+49.2%

EPS (diluted)$7.48+17.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 23, 2026

Revenue$844.9MBeat by $64.6M EPS$2.13Beat by $0.45

Read the full report

Next report

Jul 23, 2026 (In 1 week)

Revenue estimate$839.7M

EPS estimate$2.08

Financials

Q1 2026

Income statement

See full

Revenue$844.9M+21.0%

Gross profit$296.4M+27.8%

Operating income$177.1M+65.5%

Net income$138.8M+54.6%

EPS (diluted)$1.92+56.1%

Balance sheet

See full

Cash & equivalents$521.4M+29.0%

Total debt$321.0M+4.4%

Total equity$3.0B+11.5%

Total assets$4.1B+13.6%

Cash flow

See full

Operating cash flow$89.9M-30.5%

CapEx$42.7M-40.1%

Free cash flow$47.2M-18.8%

Valuation & ratios

Valuation

See full

Market cap$24.99B+56.5%

Enterprise value$24.79B+57.2%

P/E46×+13.3×

P/S7.8×+2.4×

Profitability

See full

Gross margin36.3%+1.7pp

Operating margin20.3%+1.2pp

Net margin16.8%+0.7pp

FCF margin14.2%+3.6pp

Returns & leverage

See full

Return on equity19.1%+1.7pp

Debt / equity0.1×0.0×

Current ratio2.7×-0.1×

Segments

By segment

See full

Proprietary Products$694.3M+23.3%

West Vantage$150.6M—

Competitors

By market cap

Becton, Dickinson and Company$41.5B-17.8%

West Pharmaceutical Services$25.0B+56.5%

AptarGroup$7.9B-25.5%

AVT

Avantor$6.7B-29.5%

Stevanato Group$5.3B-21.4%

Vanda Pharmaceuticals$395.7M+35.1%

Cumberland Pharmaceuticals$93.6M+98.7%

SCN

Scienture Holdings, Inc.$13.5M-29.2%

By revenue growth

West Pharmaceutical Services+11.2%

AptarGroup+9.0%

Becton, Dickinson and Company+6.4%

Cumberland Pharmaceuticals+2.1%

AVT

Avantor-2.0%

By net margin

West Pharmaceutical Services16.85%+0.7pp

AptarGroup9.98%-0.4pp

Becton, Dickinson and Company5.33%-2.1pp

AVT

Avantor-9.22%-19.9pp

Cumberland Pharmaceuticals-17.6%-9.6pp

Profile

West Pharmaceutical Services is a global leader in the design and manufacture of high-quality containment and delivery systems for injectable medicines. The company provides integrated solutions that ensure the safe and efficient administration of drugs, ranging from primary packaging components to sophisticated drug delivery devices and contract manufacturing services.

Competitive position

A dominant global player in the injectable drug containment market, characterized by high switching costs and rigorous regulatory quality standards.

GeographiesNorth America, Europe, Asia-Pacific, South America

Customer segmentsBiopharmaceutical companies, Generic drug manufacturers, Medical device OEMs

Business modelB2B Manufacturing, Contract Manufacturing (CMO), Intellectual Property Licensing

SuppliersElastomeric raw material suppliers, Specialty polymer producers, Aluminum and plastic resin suppliers

CustomersBiotechnology firms, Global pharmaceutical corporations, Contract Development and Manufacturing Organizations (CDMOs)

CountryUnited States of America

Listed1973

Employees10.6K

CEOEric Green

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitewestpharma.com

FilingsSEC EDGAR

Ask your AI about West Pharmaceutical Services.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is West Pharmaceutical Services's market cap?: West Pharmaceutical Services (WST) has a market capitalization of $25.0B and trades on NYSE.
What is West Pharmaceutical Services's revenue and profitability?: West Pharmaceutical Services generated $3.2B in trailing twelve-month revenue with net income of $542.7M, representing a net margin of 16.8%. Gross margin stands at 36.3%, with free cash flow of $458.0M. These figures are based on the Q1 2026 filing.
Who are West Pharmaceutical Services's competitors?: West Pharmaceutical Services's key competitors include AptarGroup, Inc., Stevanato Group, Becton, Dickinson and Company, and others. These companies compete in similar markets and product categories.
Who does West Pharmaceutical Services partner with?: West Pharmaceutical Services's notable partners include Daikyo Seiko, Ltd..
What subsidiaries does West Pharmaceutical Services have?: West Pharmaceutical Services's subsidiaries include Medimop Medical Projects Ltd., The Tech Group.
Where is West Pharmaceutical Services headquartered?: West Pharmaceutical Services is headquartered in United States of America and employs approximately 10,600 people. It has been publicly traded since 1973.